Companies ›Healthcare ›MIST.O

MIST.O — NASDAQ Biotechnology & Medical Research

Milestone Pharmaceuticals Inc

$1,10

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

131,6M USD

P/E

—

EV / Rev

—

Div yield

—

Op margin

-4 019,4 %

ROE

-151,0 %

Net margin

-4 078,8 %

Debt / equity

1,37

Beta

—

52w range

—

Volume

2,3k

Day range

$1,41–$1,47

Prev close

$1,40

Open

$1,47

Next earnings

2026-10-28

Ex-dividend

—

TR 1Y

—

About

Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of rare diseases, primarily in the field of oncology.

Business. Milestone Pharmaceuticals Inc (MIST.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityPharmaceuticals & Medical Research

Generated · model-assisted

Sell-side consensus

BUY6 analysts

5 buy1 hold0 sell

Avg 12m price target6,50

Analyst recommendations

6 analysts · consensus Buy

Buy5

Hold1

Sell0

12-month price target

6,50

Consensus of sell-side coverage.

Upcoming events

EarningsQ3 2026 earnings (expected)2026-10-28 · estimated

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

6 analysts · indicative

Ownership→

Goldman Sachs Asset Management, L.P.

largest disclosed fund holder

Profitability→

-151,0 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning MIST.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to MIST.O. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Company
EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Milestone Pharmaceuticals Inc (MIST.O) is a biotechnology and medical research company operating within the healthcare sector. The firm is headquartered in the United States and is primarily listed on the NASDAQ stock exchange. As no specific operating segments or geographic breakdowns are provided, the company is described at the industry level as an entity engaged in pharmaceuticals and medical research activities.

Classification92 %

SectorHealthcare

Business sectorPharmaceuticals & Medical Research

IndustryBiotechnology & Medical Research

ActivityPharmaceuticals & Medical Research

AI synthesis

GENERATED

Milestone Pharmaceuticals Inc operates with a high liquidity position, as evidenced by a current ratio of 8.01 and cash and equivalents of $73.05 million, which significantly exceeds its total liabilities of $71.79 million. The company's price-to-book ratio of 4.35 suggests that the market is valuing its equity at a premium relative to its book value, which may reflect expectations of future growth or intangible assets. However, the company's liquidity is not supported by strong cash flow generation, as it reported an operating cash flow of -$49.04 million and a free cash flow of -$63.25 million in the latest period.

Profitability metrics indicate significant underperformance relative to industry norms. The company reported a net loss of $63.06 million and an operating loss of $62.14 million, resulting in a return on equity of -1.51 and a return on assets of -0.56, both of which are negative and suggest poor capital efficiency. These figures are likely to be below the median for the biotechnology and medical research industry, where positive returns are typically expected for firms in later stages of development.

Milestone's revenue is concentrated in a single business line, as the company does not disclose segment-specific revenue data. This lack of diversification increases exposure to market volatility and regulatory changes in the biopharmaceutical sector. The company's geographic exposure is not explicitly detailed, but as a U.S.-listed firm, it is likely to derive the majority of its revenue from North America, with potential international expansion in the pipeline.

The company's growth trajectory is uncertain, as it reported revenue of $1.55 million in the latest period, with no indication of significant year-over-year growth. Analysts have provided a wide range of price targets, from $2.00 to $8.00, with a mean of $6.50 and a median of $7.50, suggesting a high degree of uncertainty about the company's future performance. The company's capital expenditures were relatively modest at -$302,000, indicating limited investment in new facilities or equipment.

Risk factors include the company's negative net income and operating income, which raise concerns about its ability to sustain operations without additional financing. The debt-to-equity ratio of 1.37 suggests that the company is leveraged, and while there are no immediate liquidity or dilution flags, the risk of future dilution remains a concern given the company's current capital structure. The company's reliance on external financing to fund operations increases its vulnerability to changes in market conditions and investor sentiment.

Recent events include the publication of analyst estimates, which show a mean recommendation of 2.00 (on a scale from 1 to 5, where 1 is "strong buy" and 5 is "strong sell"). The company has not disclosed any recent filings or transcripts that would indicate significant changes in its business strategy or financial position.

Key takeaways

Milestone Pharmaceuticals Inc has a strong liquidity position but is currently unprofitable, with a net loss of $63.06 million.
The company's price-to-book ratio of 4.35 suggests a premium valuation, but this is not supported by positive cash flow generation.
Analysts have provided a wide range of price targets, indicating uncertainty about the company's future performance.
The company's revenue is concentrated in a single business line, increasing its exposure to market volatility.
The company's debt-to-equity ratio of 1.37 suggests a leveraged capital structure, and while there are no immediate liquidity or dilution flags, the risk of future dilution remains a concern.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$1,10

Market cap

$181.8M

Enterprise valueⓘ

$166.0M

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

4.3x

P / Tangible bookⓘ

4.3x

Tangible book

$41.8M

Net cashⓘ

$15.9M

Current ratioⓘ

8.0

Debt / equityⓘ

1.4

ROAⓘ

-55.5%

ROEⓘ

-1.5%

Cash conversionⓘ

78.0%

CapEx / revenueⓘ

-19.5%

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Next quarternear-term

Earnings · next quarterconf 45 %

EPS

Consensus EPS

-0,40

Predicted surprise

+0,00

Beat probability

45 %

Analysts

Other metrics

Revenue

—

no estimate

Segment revenue

—

no estimate

Margin

—

no estimate

Segment margin

—

no estimate

as of 2026-05-22 · Earnings Surprise V1

Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.

Full fiscal year~1 year ahead

Full fiscal year · our forecast vs guidance vs consensus

Metric	Our forecast	Guidance	Consensus
EPS	—no estimate	—no estimate	-0,40
Revenue	—no estimate	—no estimate	38,0M USD
Operating income	—no estimate	—no estimate	-43,1M USD

Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.

Probabilistic model output — not investment advice. · generated 2026-08-04

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution6 analysts

Strong buy1

Buy4

Hold1

Sell0

Strong sell0

12-month price target$6,50 · Median $7,50

Low $2,00High $8,00

Operating income · consensus-43,1M USD

EPS surprise

−88,4 %

reported vs consensus · miss

Revenue surprise

−95,9 %

reported vs consensus · miss

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$2,00

Mean$6,50

Median$7,50

High$8,00

Spot$1,10

+490.9 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskLow

Filing-based flags

No immediate filing-based liquidity or dilution flags were detected.

Benchmarks vs cohort

Op Margin-4 019,4 %Bottom quartile

Net Margin-4 078,8 %Bottom quartile

ROE-151,0 %Bottom quartile

Capex / Rev-19,5 %Below median

D/E1,37Bottom quartile

Cash Conv0,78Below median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

Derivative transactions

Net acquired 3 564 000 sh5 exercises · 22 grants12 insiders

Fischer Seth H. Z.Director · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
Wills Robert JamesDirector · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
TOMSICEK MICHAEL JOHNDirector · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
Saik AndrewDirector · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
PAPA JOSEPH CDirector · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
Giles Lisa M.Director · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
Duty StuartDirector · Stock Option (right to buy) → Common StockAcquired 77 000 @ $1,22grant · 2026-06-10
Muller LorenzChief Commercial Officer · Employee Stock Option (right to buy) → Common SharesAcquired 204 000 @ $1,97grant · 2026-02-02
Bharucha DavidChief Medical Officer · Restricted Stock Unit → Common SharesAcquired 136 000grant · 2026-02-02
Oliveto JosephDirector, President and CEO · Restricted Stock Unit → Common SharesAcquired 453 000grant · 2026-02-02
Oliveto JosephDirector, President and CEO · Employee Stock Option (right to buy) → Common SharesAcquired 679 000 @ $1,97grant · 2026-02-02
Bharucha DavidChief Medical Officer · Employee Stock Option (right to buy) → Common SharesAcquired 204 000 @ $1,97grant · 2026-02-02
Nelson Jeffrey EdwardChief Operating Officer · Restricted Stock Unit → Common SharesAcquired 136 000grant · 2026-02-02
Nelson Jeffrey EdwardChief Operating Officer · Employee Stock Option (right to buy) → Common SharesAcquired 204 000 @ $1,97grant · 2026-02-02
Hasija AmitCFO & EVP of Corp. Development · Restricted Stock Unit → Common SharesAcquired 136 000grant · 2026-02-02
Hasija AmitCFO & EVP of Corp. Development · Employee Stock Option (right to buy) → Common SharesAcquired 204 000 @ $1,97grant · 2026-02-02
Muller LorenzChief Commercial Officer · Restricted Stock Unit → Common SharesAcquired 136 000grant · 2026-02-02
Bharucha DavidChief Medical Officer · Restricted Stock Units → Common SharesDisposed 20 100exercise · 2026-01-26
Muller LorenzChief Commercial Officer · Restricted Stock Units → Common SharesDisposed 20 100exercise · 2026-01-26
Oliveto JosephDirector, President and CEO · Restricted Stock Units → Common SharesDisposed 66 600exercise · 2026-01-26
Hasija AmitCFO & EVP of Corp. Development · Restricted Stock Units → Common SharesDisposed 20 100exercise · 2026-01-26
Nelson Jeffrey EdwardChief Operating Officer · Restricted Stock Units → Common SharesDisposed 20 100exercise · 2026-01-26
Bharucha DavidChief Medical Officer · Employee Stock Option (right to buy) → Common SharesAcquired 100 000 @ $1,74grant · 2025-12-12
Nelson Jeffrey EdwardChief Operating Officer · Employee Stock Option (right to buy) → Common SharesAcquired 100 000 @ $1,74grant · 2025-12-12
Muller LorenzChief Commercial Officer · Employee Stock Option (right to buy) → Common SharesAcquired 100 000 @ $1,74grant · 2025-12-12

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Return On Equity
net_income / total_equity
Price To Book
market_price / (adjusted_book_value / shares_outstanding_diluted)
Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Market Price
input from market-data provider (delayed close or quote-shim mid)
Market Cap
market_price * shares_outstanding_diluted
Ev To Revenue
enterprise_value / revenue

Source documents

Milestone Pharmaceuticals Inc Market data — financials · 2026-05-28
Milestone Pharmaceuticals Inc Market data — analyst estimates · 2026-05-28

Ownership & reference

Top holders

Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$2M
BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$7M
UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$1M
LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$1M
Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$0M
JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
Invesco QQQ TrustFunds · as of 2026-03-310,00 %$0M
Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M

Leadership

Joseph OlivetoPresident, Chief Executive Officer, Director

Insider activity

Net selling0 buys · 13 sellsnet -$1,2M5 insiders · last 365d

Oliveto JosephDirector, President and CEO · Common SharesSold 36 500 @ $2,26$82K · 2026-04-16
Muller LorenzChief Commercial Officer · Common SharesSold 11 180 @ $1,93$22K · 2026-01-26
Muller LorenzChief Commercial Officer · Common SharesOther 20 100 · 2026-01-26
Bharucha DavidChief Medical Officer · Common SharesOther 20 100 · 2026-01-26
Bharucha DavidChief Medical Officer · Common SharesSold 12 245 @ $1,93$24K · 2026-01-26
Oliveto JosephDirector, President and CEO · Common SharesSold 34 523 @ $1,93$67K · 2026-01-26
Oliveto JosephDirector, President and CEO · Common SharesOther 66 600 · 2026-01-26
Nelson Jeffrey EdwardChief Operating Officer · Common SharesOther 20 100 · 2026-01-26
Nelson Jeffrey EdwardChief Operating Officer · Common SharesSold 12 245 @ $1,93$24K · 2026-01-26
Hasija AmitCFO & EVP of Corp. Development · Common SharesSold 12 245 @ $1,93$24K · 2026-01-26
Hasija AmitCFO & EVP of Corp. Development · Common SharesOther 20 100 · 2026-01-26
Oliveto JosephDirector, President and CEO · Common SharesSold 43 000 @ $2,25$97K · 2026-01-08
Oliveto JosephDirector, President and CEO · Common SharesSold 500 @ $2,25$1K · 2026-01-07
Oliveto JosephDirector, President and CEO · Common SharesSold 133 054 @ $2,32$309K · 2025-12-15
Nelson Jeffrey EdwardChief Operating Officer · Common SharesSold 58 007 @ $2,32$135K · 2025-12-15
Hasija AmitCFO & EVP of Corp. Development · Common SharesSold 58 007 @ $2,32$135K · 2025-12-15
Bharucha DavidChief Medical Officer · Common SharesSold 58 007 @ $2,32$135K · 2025-12-15
Muller LorenzChief Commercial Officer · Common SharesSold 53 566 @ $2,32$124K · 2025-12-15
Hasija AmitCFO & EVP of Corp. Development · Common SharesOther 100 000 · 2025-12-12
Muller LorenzChief Commercial Officer · Common SharesOther 100 000 · 2025-12-12
Oliveto JosephDirector, President and CEO · Common SharesOther 280 000 · 2025-12-12
Nelson Jeffrey EdwardChief Operating Officer · Common SharesOther 100 000 · 2025-12-12
Bharucha DavidChief Medical Officer · Common SharesOther 100 000 · 2025-12-12
Muller LorenzChief Commercial Officer · Common SharesOther 25 000 · 2025-12-09

Short positioning

14.6Mshares short+15.8% vs prior

13.59days to cover

51.7%short of daily vol

83.6Kfails-to-deliver

as of 2026-07-15 · short-interest report (free)

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

MIST.OCanonical

NASDAQ · USD

Intel & risk

PredictorBeat prob45 %Surprise+0,00Full forecast →

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskLow

No immediate filing-based liquidity or dilution flags were detected.

Evidence & claims

From filings & derived data

Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 217.7%Derived (calculated)
Return on equity (FY 2025-12-31): -0.2%Derived (calculated)
Return on assets (FY 2025-12-31): -0.1%Derived (calculated)
Current ratio (FY 2025-12-31): 8.01xDerived (calculated)
Debt-to-equity (FY 2025-12-31): 1.72xDerived (calculated)
Capex (YoY) (2025-12-31 vs 2024-12-31): 815.2%Derived (calculated)
Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 188.6%Derived (calculated)
EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -11.9%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -11.9%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -51.9%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -70.0%Derived (calculated)
Operating income (YoY) (2025-12-31 vs 2024-12-31): -47.6%Derived (calculated)
R&D expense (YoY) (2025-12-31 vs 2024-12-31): 26.1%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 15.1%Derived (calculated)
Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 7.2%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): 50.4%Derived (calculated)
Operating cash flow (annual): USD -49.04MSEC XBRL filing
Current liabilities (annual): USD 13.98MSEC XBRL filing
Total liabilities (annual): USD 71.79MSEC XBRL filing
Total assets (annual): USD 113.56MSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -1SEC XBRL filing
R&D expense (annual): USD 18.11MSEC XBRL filing
Operating income (annual): USD -62.14MSEC XBRL filing
Long-term debt (annual): USD 57.19MSEC XBRL filing

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date

2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)

2026-06-15FILINGFORM 8-K →

2026-06-10 00:00 UTCINSIDER7 insider transactions — 2026-06 7 derivative

2026-06-10INSIDERPAPA JOSEPH C acquired 77.0k sh Stock Option (right to buy) — Director

2026-06-10INSIDERSaik Andrew acquired 77.0k sh Stock Option (right to buy) — Director

2026-06-10INSIDERTOMSICEK MICHAEL JOHN acquired 77.0k sh Stock Option (right to buy) — Director

2026-06-10INSIDERDuty Stuart acquired 77.0k sh Stock Option (right to buy) — Director

2026-06-10INSIDERWills Robert James acquired 77.0k sh Stock Option (right to buy) — Director

2026-06-10INSIDERGiles Lisa M. acquired 77.0k sh Stock Option (right to buy) — Director

2026-06-10INSIDERFischer Seth H. Z. acquired 77.0k sh Stock Option (right to buy) — Director

2026-05-13FILINGFORM 8-K →

2026-05-13FILING10-Q filing →

2026-04-30FILINGFORM DEF 14A →

2026-04-16 00:00 UTCINSIDER1 insider transaction — 2026-04

2026-04-16INSIDEROliveto Joseph sold 36.5k sh Common Shares — Director, President and CEO ~$82k

2026-03-20FILINGFORM 8-K →

2026-03-20FILING10-K filing →

2026-02-02 00:00 UTCINSIDER10 insider transactions — 2026-02 10 derivative

2026-02-02INSIDERMuller Lorenz acquired 204.0k sh Employee Stock Option (right to buy) — Chief Commercial Officer

2026-02-02INSIDERBharucha David acquired 136.0k sh Restricted Stock Unit — Chief Medical Officer

2026-02-02INSIDEROliveto Joseph acquired 679.0k sh Employee Stock Option (right to buy) — Director, President and CEO

2026-02-02INSIDEROliveto Joseph acquired 453.0k sh Restricted Stock Unit — Director, President and CEO

2026-02-02INSIDERHasija Amit acquired 204.0k sh Employee Stock Option (right to buy) — CFO & EVP of Corp. Development

2026-02-02INSIDERHasija Amit acquired 136.0k sh Restricted Stock Unit — CFO & EVP of Corp. Development

2026-02-02INSIDERNelson Jeffrey Edward acquired 204.0k sh Employee Stock Option (right to buy) — Chief Operating Officer

2026-02-02INSIDERNelson Jeffrey Edward acquired 136.0k sh Restricted Stock Unit — Chief Operating Officer

2026-02-02INSIDERBharucha David acquired 204.0k sh Employee Stock Option (right to buy) — Chief Medical Officer

2026-02-02INSIDERMuller Lorenz acquired 136.0k sh Restricted Stock Unit — Chief Commercial Officer

2026-01-26 00:00 UTCINSIDER17 insider transactions — 2026-01 · net sell $257k 5 derivative

2026-01-26FILINGFORM 8-K →

2026-01-26INSIDERMuller Lorenz sold 11.2k sh Common Shares — Chief Commercial Officer ~$22k

2026-01-26INSIDERMuller Lorenz transacted 20.1k sh Common Shares — Chief Commercial Officer

2026-01-26INSIDERBharucha David transacted 20.1k sh Common Shares — Chief Medical Officer

2026-01-26INSIDERBharucha David sold 12.2k sh Common Shares — Chief Medical Officer ~$24k

2026-01-26INSIDEROliveto Joseph sold 34.5k sh Common Shares — Director, President and CEO ~$67k

2026-01-26INSIDEROliveto Joseph transacted 66.6k sh Common Shares — Director, President and CEO

2026-01-26INSIDERNelson Jeffrey Edward transacted 20.1k sh Common Shares — Chief Operating Officer

2026-01-26INSIDERNelson Jeffrey Edward sold 12.2k sh Common Shares — Chief Operating Officer ~$24k

2026-01-26INSIDERHasija Amit sold 12.2k sh Common Shares — CFO & EVP of Corp. Development ~$24k

Showing the 40 most recent of 60 entries.

The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Derivative transactions

Actions

Ask Handelsavisen

Ownership & reference

Top holders

Leadership

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread